loading
Precedente Chiudi:
$149.79
Aprire:
$157.42
Volume 24 ore:
1.27M
Relative Volume:
1.15
Capitalizzazione di mercato:
$8.01B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
20.37
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+5.29%
1M Prestazione:
+10.27%
6M Prestazione:
-3.34%
1 anno Prestazione:
-28.57%
Intervallo 1D:
Value
$155.48
$167.83
Intervallo di 1 settimana:
Value
$146.26
$167.83
Portata 52W:
Value
$91.86
$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
Nome
Charles River Laboratories International Inc
Name
Telefono
781-222-6000
Name
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Name
Dipendente
20,100
Name
Cinguettio
@criverlabs
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
CRL's Discussions on Twitter

Confronta CRL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
163.13 7.76B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
425.15 160.56B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
188.77 141.52B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
527.45 42.74B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
115.99 34.11B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
188.65 27.70B 15.50B 1.33B 2.16B 7.34

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-09 Aggiornamento Citigroup Neutral → Buy
2025-05-23 Aggiornamento Redburn Atlantic Neutral → Buy
2025-05-14 Aggiornamento TD Cowen Hold → Buy
2025-05-08 Aggiornamento Evercore ISI In-line → Outperform
2025-03-21 Downgrade Goldman Buy → Neutral
2025-03-04 Aggiornamento Citigroup Sell → Neutral
2025-03-03 Aggiornamento Redburn Atlantic Sell → Neutral
2025-01-22 Downgrade William Blair Outperform → Mkt Perform
2025-01-17 Downgrade UBS Buy → Neutral
2024-11-18 Downgrade CLSA Hold → Underperform
2024-11-07 Aggiornamento CLSA Underperform → Hold
2024-10-23 Iniziato CLSA Underperform
2024-10-14 Iniziato Redburn Atlantic Sell
2024-10-07 Downgrade Evercore ISI Outperform → In-line
2024-10-02 Downgrade BofA Securities Buy → Neutral
2024-10-01 Downgrade Citigroup Neutral → Sell
2024-08-08 Downgrade JP Morgan Overweight → Neutral
2024-08-08 Downgrade Robert W. Baird Outperform → Neutral
2024-06-28 Downgrade Argus Buy → Hold
2024-06-07 Iniziato Mizuho Neutral
2024-06-06 Iniziato Goldman Buy
2024-02-15 Downgrade Guggenheim Buy → Neutral
2023-09-13 Iniziato TD Cowen Market Perform
2023-07-10 Downgrade Citigroup Buy → Neutral
2023-02-23 Aggiornamento Guggenheim Neutral → Buy
2023-01-12 Downgrade Jefferies Buy → Hold
2022-09-30 Aggiornamento Jefferies Hold → Buy
2022-08-25 Iniziato Credit Suisse Outperform
2022-08-04 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-05-24 Iniziato Guggenheim Neutral
2022-04-25 Downgrade Jefferies Buy → Hold
2022-04-07 Iniziato Stephens Overweight
2022-02-17 Reiterato BofA Securities Buy
2022-02-17 Aggiornamento Citigroup Neutral → Buy
2022-02-17 Reiterato Deutsche Bank Buy
2022-02-17 Reiterato Morgan Stanley Overweight
2022-02-17 Reiterato UBS Buy
2021-08-05 Ripresa Credit Suisse Neutral
2020-12-16 Downgrade Citigroup Buy → Neutral
2020-09-10 Aggiornamento Jefferies Hold → Buy
2020-07-01 Aggiornamento BofA Securities Neutral → Buy
2020-05-13 Aggiornamento UBS Neutral → Buy
2020-04-21 Downgrade Jefferies Buy → Hold
2020-03-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-02 Iniziato Deutsche Bank Buy
2020-02-18 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-01-10 Aggiornamento Goldman Neutral → Buy
2020-01-08 Iniziato Wells Fargo Overweight
2020-01-07 Iniziato Citigroup Buy
2019-10-18 Downgrade BofA/Merrill Buy → Neutral
2019-06-10 Iniziato SVB Leerink Outperform
2019-04-30 Ripresa Evercore ISI Outperform
2018-12-14 Iniziato Deutsche Bank Buy
2018-10-09 Iniziato UBS Neutral
2018-08-23 Aggiornamento Raymond James Mkt Perform → Outperform
2018-07-17 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2018-06-15 Aggiornamento KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 Aggiornamento SunTrust Hold → Buy
Mostra tutto

Charles River Laboratories International Inc Borsa (CRL) Ultime notizie

pulisher
12:10 PM

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

12:10 PM
pulisher
11:56 AM

Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance

11:56 AM
pulisher
11:26 AM

What drives Charles River Laboratories International Inc. stock priceDynamic investment opportunities - jammulinksnews.com

11:26 AM
pulisher
09:19 AM

Is Charles River Laboratories International Inc. a good long term investmentRapid-fire capital growth - jammulinksnews.com

09:19 AM
pulisher
08:00 AM

Gene Therapy Breakthrough: Charles River Helps Develop First Treatment for Ultra-Rare Disease in Just 13 Months - Stock Titan

08:00 AM
pulisher
07:50 AM

What analysts say about Charles River Laboratories International Inc. stockOutstanding capital returns - jammulinksnews.com

07:50 AM
pulisher
07:38 AM

Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN

07:38 AM
pulisher
Jul 21, 2025

Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com

Jul 21, 2025
pulisher
Jul 19, 2025

How Charles River Laboratories International Inc. stock reacts to Fed policy changesReal Chart Play - beatles.ru

Jul 19, 2025
pulisher
Jul 19, 2025

Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04% - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 18, 2025

Here's What To Expect From Charles River Laboratories' Next Earnings Report - Barchart.com

Jul 18, 2025
pulisher
Jul 17, 2025

Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt? - simplywall.st

Jul 17, 2025
pulisher
Jul 16, 2025

Why Charles River Laboratories International Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

CFRA downgrades Charles River Labs (CRL) to a Hold - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

Gordon Reid discusses Charles River Laboratories Intl. Inc - BNN Bloomberg

Jul 15, 2025
pulisher
Jul 15, 2025

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call - BioSpace

Jul 15, 2025
pulisher
Jul 15, 2025

Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes - Insider Monkey

Jul 15, 2025
pulisher
Jul 11, 2025

U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent

Jul 11, 2025
pulisher
Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 09, 2025

Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170 - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Jul 09, 2025
pulisher
Jul 09, 2025

Charles River Labs stock rating upgraded by Citi on DSA growth prospects - Investing.com Canada

Jul 09, 2025
pulisher
Jul 09, 2025

Cathie Wood Agrees Circle IPO Is 'Crypto's ChatGPT Moment' — Warns Institutions That Ignoring The AI-Crypto Combo 'Just Isn't An Option'Charles River (NYSE:CRL) - Benzinga

Jul 09, 2025
pulisher
Jul 08, 2025

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛

Jul 08, 2025
pulisher
Jul 03, 2025

Is Charles River Laboratories Stock Underperforming the S&P 500? - MSN

Jul 03, 2025
pulisher
Jul 02, 2025

Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds - Seeking Alpha

Jul 02, 2025
pulisher
Jul 02, 2025

Charles River Laboratories: Riding the AI Drug Discovery Wave Amid Regulatory Crosscurrents - AInvest

Jul 02, 2025
pulisher
Jun 17, 2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Jun 17, 2025
pulisher
Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Global Viral Inactivation Market | Solvent Detergent & - openPR.com

Jun 16, 2025
pulisher
Jun 14, 2025

Charles River falls after projecting 2025 revenue drop - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Medical Device Testing Market Trends | Regulatory Compliance - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Charles River Laboratories stock hits 52-week low at $160.73 - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Charles River surges after Q1 beat, guidance raise - MSN

Jun 12, 2025

Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research WAT
$290.52
price up icon 2.88%
$139.92
price down icon 0.47%
diagnostics_research DGX
$177.24
price up icon 6.50%
diagnostics_research LH
$251.53
price up icon 3.49%
diagnostics_research MTD
$1,215.49
price up icon 4.19%
diagnostics_research IQV
$188.38
price up icon 18.53%
Capitalizzazione:     |  Volume (24 ore):